New IMS high risk definition for multiple myeloma presented by Prof Corre COMy . Fantastic effort by co-operative groups to redefine risk. Clearly an evolving area.

Fantastic presentation from Ceri Bygrave on frailty, sarcopenia not only in older patients but younger ones too. COMy

Interested to see the results of IMROZ and how it may alter the pathway for newly diagnosed myeloma. A possible schema from Prof Facon COMy

Infections with bispecific antibodies in myeloma: Important to report infections per patient and standardise for follow-up time otherwise can get misleading results. New on-line calculator available! COMy

Is high levels of soluble BCMA the Achilles heel for BCMA bispecific antibodies? Another amazing talk from nizar jacques bahlis COMy

Now out in Blood Cancer Journal! 🚨 Our retrospective study at Memorial Sloan Kettering Cancer Center on the prognostic impact of steroid and tocilizumab use following commercial/investigational CAR-T for RRMM: nature.com/articles/s4140… Among 101 patients treated with BCMA- or GPRC5D-directed CAR-T,

DREAMM-7: Among patients with relapsed myeloma, median PFS was about 3 years with a regimen including the anti-BCMA antibody–drug conjugate belantamab mafodotin, as compared with about 13 months with a regimen including an anti-CD38 antibody. nej.md/3wTS3pA #ASCO24

So good to see the potential of Belantamab being demonstrated. Now we need to move to Q8 and Q12 dosing to reduce ocular tox and generate evidence for PROs in place of ocular exams.

Check out our comparative analysis of infectious complications with BCMA-directed therapies for RRMM, just published in Blood Cancer Journal: nature.com/articles/s4140… N=256 (92 CAR-T, 55 BsAb, 109 ADC). Grade ≥3 infection rates were higher with BsAbs (40%) than CAR-T (26%) or

Come and join us at 8am tomorrow at #EHA2024

Next gen CAR-T approaches for myeloma. Highlighting rapid manufacturing platforms to get CAR-at to patients faster. Great talk from Eric Smith. #EHA2024

Really enjoyed discussing how to use BCMA therapies for elderly and high risk myeloma patients with Hang Quach and Dr Lisa Leypoldt today. So much still to do to optimise these. #EHA2024

Antigen spreading as a mechanism of response for bispecifics in myeloma. But antigen loss/ mutation may be a major resistance mechanism, GPRC5D more so than BCMA. Implications for sequencing. Great talks from Leo Rasche #EHA2024

Presenting now at #EHA2024 ⬇️ Long-term follow-up of CASSIOPEIA: Bortezomib, thalidomide & dexamethasone with or w/o daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple #myeloma thelancet.com/journals/lanon…

Lovely to see you at #EHA2024 and thank you for the great patient advocacy that you do HealthTree Foundation.

Thanks for watching! COMy is a great source of topical education and debate. Highly recommend it to all. Mohamad Mohty

This is great news for UK patients. We’re actively working to overcome practical and logistical challenges to ensure patients across the country can get equitable access to BCMA bispecific antibodies. Dr Pinkie Chambers #mmsm

Great project 👇

Great news that we now have Teclistamab, another BCMA bispecific antibody available as well as Elranatamab for myeloma patients. But still more work to do to widen access to Pomalidomide exposed patients.

Check out the Summer ☀️ edition of the UCLH Early Phase Cancer Trials Newsletter 📰: ucl.ac.uk/early-phase-ca…